TL6: Recent Advances in Turning Adaptive Designs Theory for Phase I Oncology Trials into Practice
*Inna Perevozskaya, Pfizer 

Keywords: phase 1 oncology. maximum tolerated dose, adaptive design

Phase 1 oncology drug development recently has experienced a surge in usage of adaptive trial designs. When carefully designed and executed, such trials can offer significant advantage over 3+3 design in precision of Maximum Tolerated Dose estimation. There are quite a few adaptive options available for phase 1 oncology trials today; the level of their utilization varies greatly within pharmaceutical industry and academia alike. In this roundtable discussion, we will focus on case studies and actual experiences of planning and running these trials, including what it takes to make these methods broadly acceptable and what challenges are faced along the way.